News | December 21, 2023
AGC invests US$ 348 million to expand its biopharmaceutical CDMO capability
Development services for gene and cell therapies is planned to begin first in 2025
Development services for gene and cell therapies is planned to begin first in 2025
Three block copolymers added to RESOMER portfolio of bioabsorbable polymers
New Board of Directors and management team at Suven Pharma also appointed
In 2030 over 50% of FDA approvals will involve AI discovered and developed drugs
Pharma in Korea receives a 7% increase in ‘growth potential’ category according to the CPHI Annual Survey findings
Evonik specializes in mid- to large-scale, later clinical phase HPAPIs
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
China is now focusing on establishing volume and enhancing capabilities for innovative high value drug production
Steve joins Sai Life Sciences from GlaxoSmithKline (GSK) where he was a department head and member of the global chemical development leadership team.
Subscribe To Our Newsletter & Stay Updated
